Saúde Pública em Pediatria

Revisão | Prevenção da aterosclerose a partir da infância.

4 Fev, 2022 | 15:33h

Prevention of atherosclerosis from childhood – Nature Reviews Cardiology (se o acesso a este link for pago, tente este)

Um estudo de coorte de amplitude nacional na Dinamarca mostrou que a “long Covid” em crianças é rara e de curta duração.

31 Jan, 2022 | 09:00h

Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study – European Journal of Pediatrics

Conteúdos relacionados:

E ditorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Comentário no Twitter

Absolutely HUGE study on persistent symptoms after #COVID19 ("long covid") in 37,000 children from Denmark 🇩🇰

Incidence 0.8% compared to controls

Most symptoms resolved in <5 months (often loss of smell/taste)

Reassuring news from biggest study yet✅https://t.co/vX2JFruOqe pic.twitter.com/GctgyMXn6I

— Alasdair Munro (@apsmunro) January 28, 2022

Miocardite após vacinação de adolescentes com BNT162b2 em Israel.

31 Jan, 2022 | 08:55h

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine

Conteúdos relacionados:

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Comentário no Twitter

Data from the Israeli MOH show estimates of myocarditis risk in the 21 days after a first & second dose of vaccine were 0.56 per 100,000 and 8.09 per 100,000 among male recipients and 0 per 100,000 and 0.69 per 100,000 among females. https://t.co/M6kxVA2toS pic.twitter.com/bQ4TBmcrj4

— NEJM (@NEJM) January 29, 2022